BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35483190)

  • 1. Oleanolic acid combined with olaparib enhances radiosensitization in triple negative breast cancer and hypoxia imaging with
    Xu AL; Xue YY; Tao WT; Wang SQ; Xu HQ
    Biomed Pharmacother; 2022 Jun; 150():113007. PubMed ID: 35483190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
    Wang W; Duan B; Zeng L
    Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.
    Senra JM; Telfer BA; Cherry KE; McCrudden CM; Hirst DG; O'Connor MJ; Wedge SR; Stratford IJ
    Mol Cancer Ther; 2011 Oct; 10(10):1949-58. PubMed ID: 21825006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.
    Karnak D; Engelke CG; Parsels LA; Kausar T; Wei D; Robertson JR; Marsh KB; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
    Clin Cancer Res; 2014 Oct; 20(19):5085-96. PubMed ID: 25117293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced Anti-Cancer Effect of Folate-Conjugated Olaparib Nanoparticles Combined with Radiotherapy in Cervical Carcinoma.
    Li D; Hu C; Yang J; Liao Y; Chen Y; Fu SZ; Wu JB
    Int J Nanomedicine; 2020; 15():10045-10058. PubMed ID: 33328733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.
    Pierce A; McGowan PM; Cotter M; Mullooly M; O'Donovan N; Rani S; O'Driscoll L; Crown J; Duffy MJ
    Cancer Biol Ther; 2013 Jun; 14(6):537-45. PubMed ID: 23760496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression of APE1 in triple-negative breast cancer and its effect on drug sensitivity of olaparib.
    Chen T; Liu C; Lu H; Yin M; Shao C; Hu X; Wu J; Wang Y
    Tumour Biol; 2017 Oct; 39(10):1010428317713390. PubMed ID: 29064327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia Imaging and Biological Evaluation of the Radiosensitizing Effect of Oleanolic Acid.
    Wang H; Zhang Y; Yu W; Xue Y; Xiao L; Xu H
    Biomed Res Int; 2018; 2018():2694679. PubMed ID: 30246018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Poly(ADP-ribose) Polymerase Sensitizes [
    Bao G; Zhou H; Zou S; Chen L; Zhang B; Wang Z; Moon ES; Zhao J; Roesch F; Zhu X
    Mol Pharm; 2023 May; 20(5):2443-2451. PubMed ID: 37067162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells.
    Liu C; Gross N; Li Y; Li G; Wang Z; Zhong S; Li Y; Hu G
    J Cell Mol Med; 2020 Feb; 24(4):2444-2450. PubMed ID: 31957270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality.
    Jiang Y; Verbiest T; Devery AM; Bokobza SM; Weber AM; Leszczynska KB; Hammond EM; Ryan AJ
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):772-81. PubMed ID: 27020103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of olaparib and camptothecin for effective radiosensitization.
    Miura K; Sakata K; Someya M; Matsumoto Y; Matsumoto H; Takahashi A; Hareyama M
    Radiat Oncol; 2012 Apr; 7():62. PubMed ID: 22524618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
    Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
    J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olaparib nanoparticles potentiated radiosensitization effects on lung cancer.
    Wu M; Liu J; Hu C; Li D; Yang J; Wu Z; Yang L; Chen Y; Fu S; Wu J
    Int J Nanomedicine; 2018; 13():8461-8472. PubMed ID: 30587971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly (ADP-ribose) polymerase inhibitors sensitize cancer cells to hypofractionated radiotherapy through altered selection of DNA double-strand break repair pathways.
    Seo Y; Tamari K; Takahashi Y; Minami K; Tatekawa S; Isohashi F; Suzuki O; Akino Y; Ogawa K
    Int J Radiat Biol; 2022; 98(7):1222-1234. PubMed ID: 34919022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
    Bi Y; Verginadis II; Dey S; Lin L; Guo L; Zheng Y; Koumenis C
    Gynecol Oncol; 2018 Sep; 150(3):534-544. PubMed ID: 30025822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.